Rhenman & Partners Asset Management’s INmune Bio INMB Stock Holding History

Rhenman & Partners Asset Management’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-178,284	Closed	-$412K	–	96
2025 Q2	$412K	Hold	178,284	–	–	0.05%	90
2025 Q1	$1.39M	Hold	178,284	–	–	0.16%	74
2024 Q4	$833K	Hold	178,284	–	–	0.09%	88
2024 Q3	$961K	Hold	178,284	–	–	0.08%	95
2024 Q2	$1.57M	Hold	178,284	–	–	0.15%	80
2024 Q1	$2.09M	Hold	178,284	–	–	0.2%	75
2023 Q4	$2.01M	Hold	178,284	–	–	0.2%	74
2023 Q3	$1.22M	Hold	178,284	–	–	0.13%	80
2023 Q2	$1.62M	Buy	+178,284	New	+$1.43M	0.17%	77

Other funds holding INMB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rhenman & Partners Asset Management's INMB Position: Q3 2025 in Review

Rhenman & Partners Asset Management sold out of INmune Bio (INMB) in Q3 2025, closing a stake of 178,284 shares — an estimated $412K sold.

Rhenman & Partners Asset Management first reported a position in INMB in Q2 2023 and held it in 9 quarters. The position peaked at $2.09M in Q1 2024. 73 funds tracked by Wall St. Rank hold INMB as of Q3 2025.

Rhenman & Partners Asset Management reported no remaining INmune Bio position as of Q3 2025 after selling out during the quarter.
Rhenman & Partners Asset Management sold 178,284 INmune Bio shares in Q3 2025, an estimated $412K.
Rhenman & Partners Asset Management first reported a position in INmune Bio in Q2 2023 and held it in 9 quarters.
Rhenman & Partners Asset Management's INmune Bio position peaked at $2.09M in Q1 2024.
73 funds tracked by Wall St. Rank held INmune Bio as of Q3 2025.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.